Study of the Sars-Cov2 Neuroinvasiveness - COVID19
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Percentage of patients with COVID-19 positive samples/biopsies
研究概览
简要总结
Sars-Cov2 (COVID-19) may invade the CNS inducing neurological diseases such as anosmia, ageusia, encephalitis, ischemic or hemorrhagic stroke. Management of severe neurological complications in COVID-19 patients may require ventricular cerebrospinal fluid drainage and cranial decompression. During surgery, cerebrospinal fluid, meninges and brain parenchyma can be safely removed from the patient. In this study, COVID-19 patients will be evaluated first, for the presence of Sars-Cov2 in the cerebrospinal fluid and/or biopsies and second, for the consequences of Sars-Cov2 neuroinfection in terms of inflammatory and immune responses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •COVID-19 patients requiring an external ventricular drain, a decompressive craniectomy or an intracranial hematoma surgery
排除标准
- •Pregnant or lactating women
研究组 & 干预措施
Neurological biological samples
干预措施: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies (Drug)
结局指标
主要结局
Percentage of patients with COVID-19 positive samples/biopsies
时间窗: At the time of the inclusion
COVID-19 RT-PCR test
次要结局
未报告次要终点